6th May 2014 18:16
BLOCK LISTING SIX MONTHLY RETURN
VERNALIS PLC (the "Company")
6 May 2014
Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:
Name of applicant: | Vernalis plc | |
Name of scheme(s): | 2007 Long Term Incentive Scheme and the Savings Related Share Option Plan 2003 | |
Period of return (from / to): | From: 06/Nov/2013 | To: 06/May/2014 |
Balance of unallotted securities under scheme(s) from previous return: | 0 Ordinary 1p Shares | |
Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for): | 1,399,317 Ordinary 1p Shares | |
Less: Number of securities issued/allotted under scheme(s) during period: | 29,880 Ordinary 1p Shares | |
Less: Number of securities forfeited under scheme(s) during period: | NIL | |
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1,369,437 Ordinary 1p Shares | |
Number and class of securities originally admitted and the date of admission (including any additions): | 350,000 Ordinary 1p Shares admitted on 6 November 2013. A block listing application for 1,049,317 Ordinary 1p Shares has been made on 6 May 2014 and admission is expected to take place on 12 May 2014. | |
-- ends -
Enquiries:
Vernalis: | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Canaccord Genuity Limited (Nominated Adviser): | +44 (0) 20 7523 8350 |
Lucy Tilley Dr Julian Feneley Henry Fitzgerald-O'Connor
| |
Shore Capital (Joint Broker): | +44 (0)20 7408 4090 |
Bidhi Bhoma Toby Gibbs
| |
Brunswick Group: | +44 (0) 20 7404 5959 |
Jon Coles
|
Notes to Editors
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com
Related Shares:
Vernalis PLC